Organon
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
DitchCarbon Score
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon's score of 31 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon's reported carbon emissions
In 2023, Organon reported total carbon emissions of approximately 7,000,000 kg CO2e in the UK, comprising 2,272,000 kg CO2e from Scope 1 and 5,557,000 kg CO2e from Scope 2 emissions. Additionally, their Scope 3 emissions included 415,000 kg CO2e from business travel, 830,000 kg CO2e from employee commuting, 130,000 kg CO2e from waste generated in operations, and 1,840,000 kg CO2e from transportation and distribution activities (both upstream and downstream). In 2022, Organon's emissions in the UK were slightly lower, with total emissions of about 6,000,000 kg CO2e, including 1,122,000 kg CO2e from Scope 1 and 5,677,000 kg CO2e from Scope 2. Their Scope 3 emissions for that year were notably higher, with significant contributions from employee commuting and transportation. Globally, in 2021, Organon reported total emissions of approximately 57,899,000 kg CO2e, with Scope 1 emissions at 32,014,000 kg CO2e and Scope 2 emissions at 32,918,000 kg CO2e. The company has not disclosed specific reduction targets or initiatives as part of their climate commitments, indicating a potential area for future focus. Overall, Organon is actively monitoring its carbon footprint across all scopes of emissions, but further details on specific reduction strategies or targets are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
